| Views | |
|---|---|
| Antinuclear antibodies are common and linked to poor response to omalizumab treatment in patients with CSU | 96 |
| January 2025 | February 2025 | March 2025 | April 2025 | May 2025 | June 2025 | July 2025 | |
|---|---|---|---|---|---|---|---|
| Antinuclear antibodies are common and linked to poor response to omalizumab treatment in patients with CSU | 3 | 1 | 3 | 12 | 0 | 3 | 0 |
| Views | |
|---|---|
| 2019_Ertaş_etal.pdf | 209 |
| 2019_Ertaş_etal.pdf | 6 |
